RIBOMIC Inc. announced that the first dose of RBM-007 (anti-FGF2 aptamer) was administered to a pediatric patient with Achondroplasia in the early phase II study to investigate the efficacy and safety of RBM-007. RBM-007 is a novel nucleic acid medicine (oligonucleotide-based aptamer) developed in-house at RIBOMIC's research facilities in Tokyo. RBM-007 has been shown to have potent effects in limiting excessive interactions between fibroblast growth factors, which are known to cause achondroplasia.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
86 JPY | +3.61% | +4.88% | -20.37% |
1st Jan change | Capi. | |
---|---|---|
-20.37% | 20.25M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- 4591 Stock
- News Ribomic Inc.
- RIBOMIC, Inc. Announces Start of Administration of RBM-007, Achondroplasia Investigational Drug, to the First Patient in the Early Phase II Study in Japan